BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 30309219)

  • 1. Risk Assessment of Secondary Primary Malignancies in Nasopharyngeal Carcinoma: A Big-Data Intelligence Platform-Based Analysis of 6,377 Long-term Survivors from an Endemic Area Treated with Intensity-Modulated Radiation Therapy during 2003-2013.
    Zhang LL; Li GH; Li YY; Qi ZY; Lin AH; Sun Y
    Cancer Res Treat; 2019 Jul; 51(3):982-991. PubMed ID: 30309219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second primary cancer after intensity-modulated radiotherapy for nasopharyngeal carcinoma: A territory-wide study by HKNPCSG.
    Chow JCH; Tam AHP; Cheung KM; Lee VHF; Chiang CL; Tong M; Wong ECY; Cheung AKW; Chan SPC; Lai JWY; Ngan RKC; Ng WT; Lee AWM; Au KH
    Oral Oncol; 2020 Dec; 111():105012. PubMed ID: 32980659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk, pattern and survival impact of second primary tumors in patients with nasopharyngeal carcinoma following definitive intensity-modulated radiotherapy.
    Chow JCH; Au KH; Mang OWK; Cheung KM; Ngan RKC
    Asia Pac J Clin Oncol; 2019 Feb; 15(1):48-55. PubMed ID: 29932287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical characteristics of secondary primary tumors in patients with nasopharyngeal carcinoma after intensity-modulated radiotherapy: A retrospective analysis.
    Zhao W; Lei H; Zhu X; Li L; Qu S; Liang X; Wang X
    Medicine (Baltimore); 2016 Nov; 95(45):e5364. PubMed ID: 27828863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical features and survival outcomes between ascending and descending types of nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A big-data intelligence platform-based analysis.
    Yao JJ; Qi ZY; Liu ZG; Jiang GM; Xu XW; Chen SY; Zhu FT; Zhang WJ; Lawrence WR; Ma J; Zhou GQ; Sun Y
    Radiother Oncol; 2019 Aug; 137():137-144. PubMed ID: 31102988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Competing risk nomograms for nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A big-data, intelligence platform-based analysis.
    Huang XD; Zhou GQ; Lv JW; Zhou HQ; Zhong CW; Wu CF; Zheng ZQ; He XJ; Peng L; Ma J; Sun Y
    Radiother Oncol; 2018 Nov; 129(2):389-395. PubMed ID: 30270098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advantages of using reduced-volume intensity modulated radiation therapy for the treatment of nasopharyngeal carcinoma: a retrospective paired study.
    Liu F; Luo T; Jin T; Zhang J; Xiang Z; Yan R; Xie L; Wu X; Zhang H; Wang F; Li P; Liu L
    BMC Cancer; 2019 Jun; 19(1):554. PubMed ID: 31176358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival impact of radiotherapy interruption in nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A big-data intelligence platform-based analysis.
    Yao JJ; Zhang F; Gao TS; Zhang WJ; Lawrence WR; Zhu BT; Zhou GQ; Ma J; Wang SY; Sun Y
    Radiother Oncol; 2019 Mar; 132():178-187. PubMed ID: 30448002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction chemotherapy plus IMRT alone versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
    Wei Z; Zhang Z; Luo J; Li N; Peng X
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1857-1864. PubMed ID: 31062162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival without concurrent chemotherapy for locoregionally advanced nasopharyngeal carcinoma treated with induction chemotherapy plus intensity-modulated radiotherapy: Single-center experience from an endemic area.
    Fangzheng W; Chuner J; Haiyan Q; Quanquan S; Zhimin Y; Tongxin L; Jiping L; Peng W; Kaiyuan S; Zhenfu F; Yangming J
    Medicine (Baltimore); 2019 Dec; 98(51):e18484. PubMed ID: 31861031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nasopharyngeal carcinoma in children and adolescents in an endemic area: a report of 185 cases.
    Yan Z; Xia L; Huang Y; Chen P; Jiang L; Zhang B
    Int J Pediatr Otorhinolaryngol; 2013 Sep; 77(9):1454-60. PubMed ID: 23830224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost.
    Ou X; Zhou X; Shi Q; Xing X; Yang Y; Xu T; Shen C; Wang X; He X; Kong L; Ying H; Hu C
    Oncotarget; 2015 Nov; 6(35):38381-97. PubMed ID: 26485757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The effect of overall treatment time on local control in nasopharyngeal carcinoma patients treated with intensity modulated radiation therapy].
    Su SF; Han F; Zhao C; Chen CY; Xiao WW; Li JX; Lu TX
    Zhonghua Yi Xue Za Zhi; 2011 Feb; 91(7):469-72. PubMed ID: 21418978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dosimetric predictors of temporal lobe injury after intensity-modulated radiotherapy for T4 nasopharyngeal carcinoma: a competing risk study.
    Huang J; Kong FF; Oei RW; Zhai RP; Hu CS; Ying HM
    Radiat Oncol; 2019 Feb; 14(1):31. PubMed ID: 30736809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.
    Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ
    Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimally invasive surgery alone compared with intensity-modulated radiotherapy for primary stage I nasopharyngeal carcinoma.
    Liu YP; Lv X; Zou X; Hua YJ; You R; Yang Q; Xia L; Guo SY; Hu W; Zhang MX; Chen SY; Lin M; Xie YL; Liu LZ; Sun R; Huang PY; Fan W; Guo X; Hong MH; Chen MY
    Cancer Commun (Lond); 2019 Nov; 39(1):75. PubMed ID: 31730020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostication of serial post-intensity-modulated radiation therapy undetectable plasma EBV DNA for nasopharyngeal carcinoma.
    Lee VH; Kwong DL; Leung TW; Choi CW; Lai V; Ng L; Lam KO; Ng SC; Sze CK; Tong CC; Ho PP; Chan WL; Wong LS; Leung DK; Chan SY; Khong PL
    Oncotarget; 2017 Jan; 8(3):5292-5308. PubMed ID: 28029657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proposal of a Pretreatment Nomogram for Predicting Local Recurrence after Intensity-Modulated Radiation Therapy in T4 Nasopharyngeal Carcinoma: A Retrospective Review of 415 Chinese Patients.
    Zhang LL; Li YY; Hu J; Zhou GQ; Chen L; Li WF; Lin AH; Ma J; Qi ZY; Sun Y
    Cancer Res Treat; 2018 Oct; 50(4):1084-1095. PubMed ID: 29141396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term Therapeutic Outcome and Prognostic Factors of Patients with Nasopharyngeal Carcinoma Receiving Intensity-modulated Radiotherapy: An Analysis of 608 Patients from Low-endemic Regions of China.
    Huang J; Yang ZY; Wu B; Ding Q; Qin Y; Zhang ZJ; Yin ZY; Liang ZW; Han J; Wang Y; Peng ZJ; Peng G; Li Q; Wu G; Yang KY
    Curr Med Sci; 2021 Aug; 41(4):737-745. PubMed ID: 34403099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of small lymph node metastases in patients with nasopharyngeal carcinoma: Clinical implications for prognosis and treatment.
    Xu P; Min Y; Blanchard P; Feng M; Zhang P; Luo Y; Fan Z; Lang J
    Head Neck; 2017 Feb; 39(2):305-310. PubMed ID: 27627795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.